Common Contracts
3 similar Patent License Agreement contracts by AIkido Pharma Inc., Silo Pharma, Inc.
Patent License AgreementPatent License Agreement • April 16th, 2021 • AIkido Pharma Inc. • Services-commercial physical & biological research • New York
This Patent License Agreement (this “Agreement”) is effective as of the date of the last signature on the signature page (the “Effective Date”), and is made by and between SILO PHARMA INC., a Delaware Corporation, and SILO PHARMA, INC., a Florida Corporation, and their Affiliates/Subsidiaries, as defined below, with principal executive offices located at 560 Sylvan Avenue, Suite 3160, Englewood Cliffs, New Jersey 07632 (collectively, “Licensor”), on the one hand, and AIKIDO PHARMA INC., a Delaware corporation, principal executive offices located at One Rockefeller Plaza, 11th Floor, New York, New York 10020 (“Licensee”), on the other hand (collectively, the “Parties,” or each, individually, a “Party”).
AMENDMENT NO. 1 TO PATENT LICENSE AGREEMENTPatent License Agreement • April 16th, 2021 • AIkido Pharma Inc. • Services-commercial physical & biological research • New York
This Amendment No. 1 (this “Amendment”) to the Patent License Agreement (as defined below) is made and entered into as of April 12, 2021, by and among Silo Pharma Inc., a Delaware corporation, Silo Pharma, Inc., a Florida corporation, and their Affiliates/Subsidiaries, (the “Licensor”), on the one hand and AIkido Pharma Inc., a Delaware corporation (the “Licensee”) on the other hand (collectively, the “Parties,” or each, individually, a “Party”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Patent License Agreement.
Patent License AgreementPatent License Agreement • January 11th, 2021 • Silo Pharma, Inc. • Apparel & other finishd prods of fabrics & similar matl • New York
This Patent License Agreement (this “Agreement”) is effective as of the date of the last signature on the signature page (the “Effective Date”), and is made by and between SILO PHARMA INC., a Delaware Corporation, and SILO PHARMA, INC., a Florida Corporation, and their Affiliates/Subsidiaries, as defined below, with principal executive offices located at 560 Sylvan Avenue, Suite 3160, Englewood Cliffs, New Jersey 07632 (collectively, “Licensor”), on the one hand, and AIKIDO PHARMA INC., a Delaware corporation, principal executive offices located at One Rockefeller Plaza, 11th Floor, New York, New York 10020 (“Licensee”), on the other hand (collectively, the “Parties,” or each, individually, a “Party”).
